BML Capital Management »

Design Therapeutics shares owned by BML Capital Management

Quarter-by-quarter ownership of Design Therapeutics (DSGN) shares owned by BML Capital Management from 13F filings

Historical chart of BML Capital Management investment in Design Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Design Therapeutics held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Design Therapeutics by BML Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.5M 880k 4.03
2023-12-31 $2.7M 1.0M 2.65

More positions owned by BML Capital Management

Ishares Tr 0-3 Mnth Treasry (SGOV)
Atea Pharmaceuticals (AVIR)
Spdr Ser Tr Bloomberg 1-3 Mo (BIL)
Adverum Biotechnologies Com New
Aclaris Therapeutics (ACRS)
Cyteir Therapeutics
Eliem Therapeutics (ELYM)
Avrobio Ord (AVRO)
Instil Bio Com New (TIL)
Reneo Pharmaceuticals (RPHM)
Connect Biopharma Hldgs Ads (CNTB)
Design Therapeutics (DSGN)
Athira Pharma (ATHA)
Oramed Pharmaceuticals Com New (ORMP)
Pmv Pharmaceuticals (PMVP)

View all positions for BML Capital Management

Top funds holding Design Therapeutics

Sr One Capital Management
Logos Global Management
Citadel Advisors
Baker Bros. Advisors
Tang Capital Management
Almitas Capital
Goldman Sachs Group
Vanguard Group
BML Capital Management
Two Sigma Advisers
Jacobs Levy Equity Management
Two Sigma Investments
Millennium Management
Walleye Trading Advisors
Assenagon Asset Management

View all funds holding Design Therapeutics